APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Gene Therapies for Tumor Treatment

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Gene Therapies for Tumor Treatment Market Analysis and Forecast 2026-2032

Report ID 173994600220 December 2025197 pages

Choose your research edition.

Industry ResearchGene Therapies for Tumor Treatment Industry Research Report 2026110 pages · $2,950 USDIndustry Growth & TrendsGlobal Gene Therapies for Tumor Treatment Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Gene Therapies for Tumor Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gene Therapies for Tumor Treatment Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Gene Therapies for Tumor Treatment Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Gene Therapies for Tumor Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Gene Therapies for Tumor Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Gene Therapies for Tumor Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Gene Therapies for Tumor Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Gene Therapies for Tumor Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Gene Therapies for Tumor Treatment include Shanghai Sunway, Novartis, Amgen, Sibiono and Gilead Sciences, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Gene Therapies for Tumor Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Gene Therapies for Tumor Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Gene Therapies for Tumor Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Gene Therapies for Tumor Treatment revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Gene Therapies for Tumor Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Gene Therapies for Tumor Treatment revenue, projected growth trends, production technology, application and end-user industry.

Gene Therapies for Tumor Treatment Segment by Company

Shanghai Sunway

Novartis

Amgen

Sibiono

Gilead Sciences

Gene Therapies for Tumor Treatment Segment by Type

Oncolytic Virotherapy

Gene Transfer

Gene Induced Immunotherapy

Gene Therapies for Tumor Treatment Segment by Application

Hospital

Clinic

Other

Gene Therapies for Tumor Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gene Therapies for Tumor Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gene Therapies for Tumor Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gene Therapies for Tumor Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Gene Therapies for Tumor Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Gene Therapies for Tumor Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Gene Therapies for Tumor Treatment revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Gene Therapies for Tumor Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Oncolytic Virotherapy Major Player Table 3. Gene Transfer Major Player Table 4. Gene Induced Immunotherapy Major Player Table 5. Global Gene Therapies for Tumor Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospital Major Player Table 7. Clinic Major Player Table 8. Other Major Player Table 9. Gene Therapies for Tumor Treatment Industry Trends Table 10. Gene Therapies for Tumor Treatment Industry Drivers Table 11. Gene Therapies for Tumor Treatment Industry Opportunities and Challenges Table 12. Gene Therapies for Tumor Treatment Industry Restraints Table 13. Global Gene Therapies for Tumor Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Gene Therapies for Tumor Treatment Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Gene Therapies for Tumor Treatment Market Share by Region (2021-2026) Table 16. Global Gene Therapies for Tumor Treatment Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Gene Therapies for Tumor Treatment Market Share by Region (2027-2032) Table 18. Global Gene Therapies for Tumor Treatment Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Gene Therapies for Tumor Treatment Revenue Market Share by Players (2021-2026) Table 20. Global Gene Therapies for Tumor Treatment Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Gene Therapies for Tumor Treatment Key Players Headquarters & Area Served Table 22. Global Gene Therapies for Tumor Treatment Players, Product Type & Application Table 23. Global Gene Therapies for Tumor Treatment Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Gene Therapies for Tumor Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Gene Therapies for Tumor Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Gene Therapies for Tumor Treatment Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Gene Therapies for Tumor Treatment Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Gene Therapies for Tumor Treatment Revenue Market Share by Type (2021-2026) Table 30. Global Gene Therapies for Tumor Treatment Revenue Market Share by Type (2027-2032) Table 31. Global Gene Therapies for Tumor Treatment Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Gene Therapies for Tumor Treatment Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Gene Therapies for Tumor Treatment Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Gene Therapies for Tumor Treatment Revenue Market Share by Application (2021-2026) Table 35. Global Gene Therapies for Tumor Treatment Revenue Market Share by Application (2027-2032) Table 36. Shanghai Sunway Company Information Table 37. Shanghai Sunway Business Overview Table 38. Shanghai Sunway Gene Therapies for Tumor Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Shanghai Sunway Gene Therapies for Tumor Treatment Product Portfolio Table 40. Shanghai Sunway Recent Development Table 41. Novartis Company Information Table 42. Novartis Business Overview Table 43. Novartis Gene Therapies for Tumor Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Novartis Gene Therapies for Tumor Treatment Product Portfolio Table 45. Novartis Recent Development Table 46. Amgen Company Information Table 47. Amgen Business Overview Table 48. Amgen Gene Therapies for Tumor Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Amgen Gene Therapies for Tumor Treatment Product Portfolio Table 50. Amgen Recent Development Table 51. Sibiono Company Information Table 52. Sibiono Business Overview Table 53. Sibiono Gene Therapies for Tumor Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Sibiono Gene Therapies for Tumor Treatment Product Portfolio Table 55. Sibiono Recent Development Table 56. Gilead Sciences Company Information Table 57. Gilead Sciences Business Overview Table 58. Gilead Sciences Gene Therapies for Tumor Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Gilead Sciences Gene Therapies for Tumor Treatment Product Portfolio Table 60. Gilead Sciences Recent Development Table 61. North America Gene Therapies for Tumor Treatment Revenue by Type (2021-2026) & (US$ Million) Table 62. North America Gene Therapies for Tumor Treatment Revenue by Type (2027-2032) & (US$ Million) Table 63. North America Gene Therapies for Tumor Treatment Revenue by Application (2021-2026) & (US$ Million) Table 64. North America Gene Therapies for Tumor Treatment Revenue by Application (2027-2032) & (US$ Million) Table 65. North America Gene Therapies for Tumor Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 66. North America Gene Therapies for Tumor Treatment Revenue by Country (2021-2026) & (US$ Million) Table 67. North America Gene Therapies for Tumor Treatment Revenue by Country (US$ Million) & (2027-2032) Table 68. Europe Gene Therapies for Tumor Treatment Revenue by Type (2021-2026) & (US$ Million) Table 69. Europe Gene Therapies for Tumor Treatment Revenue by Type (2027-2032) & (US$ Million) Table 70. Europe Gene Therapies for Tumor Treatment Revenue by Application (2021-2026) & (US$ Million) Table 71. Europe Gene Therapies for Tumor Treatment Revenue by Application (2027-2032) & (US$ Million) Table 72. Europe Gene Therapies for Tumor Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 73. Europe Gene Therapies for Tumor Treatment Revenue by Country (2021-2026) & (US$ Million) Table 74. Europe Gene Therapies for Tumor Treatment Revenue by Country (US$ Million) & (2027-2032) Table 75. China Gene Therapies for Tumor Treatment Revenue by Type (2021-2026) & (US$ Million) Table 76. China Gene Therapies for Tumor Treatment Revenue by Type (2027-2032) & (US$ Million) Table 77. China Gene Therapies for Tumor Treatment Revenue by Application (2021-2026) & (US$ Million) Table 78. China Gene Therapies for Tumor Treatment Revenue by Application (2027-2032) & (US$ Million) Table 79. Asia Gene Therapies for Tumor Treatment Revenue by Type (2021-2026) & (US$ Million) Table 80. Asia Gene Therapies for Tumor Treatment Revenue by Type (2027-2032) & (US$ Million) Table 81. Asia Gene Therapies for Tumor Treatment Revenue by Application (2021-2026) & (US$ Million) Table 82. Asia Gene Therapies for Tumor Treatment Revenue by Application (2027-2032) & (US$ Million) Table 83. Asia Gene Therapies for Tumor Treatment Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 84. Asia Gene Therapies for Tumor Treatment Revenue by Region (US$ Million) & (2021-2026) Table 85. Asia Gene Therapies for Tumor Treatment Revenue by Region (US$ Million) & (2027-2032) Table 86. SAMEA Gene Therapies for Tumor Treatment Revenue by Type (2021-2026) & (US$ Million) Table 87. SAMEA Gene Therapies for Tumor Treatment Revenue by Type (2027-2032) & (US$ Million) Table 88. SAMEA Gene Therapies for Tumor Treatment Revenue by Application (2021-2026) & (US$ Million) Table 89. SAMEA Gene Therapies for Tumor Treatment Revenue by Application (2027-2032) & (US$ Million) Table 90. SAMEA Gene Therapies for Tumor Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 91. SAMEA Gene Therapies for Tumor Treatment Revenue by Country (2021-2026) & (US$ Million) Table 92. SAMEA Gene Therapies for Tumor Treatment Revenue by Country (US$ Million) & (2027-2032) Table 93. Research Programs/Design for This Report Table 94. Authors List of This Report Table 95. Secondary Sources Table 96. Primary Sources List of Figures Figure 1. Gene Therapies for Tumor Treatment Image Figure 2. Global Gene Therapies for Tumor Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gene Therapies for Tumor Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. Oncolytic Virotherapy Image Figure 5. Gene Transfer Image Figure 6. Gene Induced Immunotherapy Image Figure 7. Global Gene Therapies for Tumor Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Gene Therapies for Tumor Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospital Image Figure 10. Clinic Image Figure 11. Other Image Figure 12. Global Gene Therapies for Tumor Treatment Market Size (US$ Million) & (2021-2032) Figure 13. Global Gene Therapies for Tumor Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Gene Therapies for Tumor Treatment Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Gene Therapies for Tumor Treatment Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Gene Therapies for Tumor Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Gene Therapies for Tumor Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Gene Therapies for Tumor Treatment Revenue Market Share by Type (2021-2032) Figure 20. Global Gene Therapies for Tumor Treatment Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Gene Therapies for Tumor Treatment Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Gene Therapies for Tumor Treatment Revenue Market Share by Application (2021-2032) Figure 23. North America Gene Therapies for Tumor Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Gene Therapies for Tumor Treatment Revenue Share by Type (2021-2032) Figure 25. North America Gene Therapies for Tumor Treatment Revenue Share by Application (2021-2032) Figure 26. North America Gene Therapies for Tumor Treatment Revenue Share by Country (2021-2032) Figure 27. United States Gene Therapies for Tumor Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Gene Therapies for Tumor Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Gene Therapies for Tumor Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Gene Therapies for Tumor Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Gene Therapies for Tumor Treatment Revenue Share by Type (2021-2032) Figure 32. Europe Gene Therapies for Tumor Treatment Revenue Share by Application (2021-2032) Figure 33. Europe Gene Therapies for Tumor Treatment Revenue Share by Country (2021-2032) Figure 34. Germany Gene Therapies for Tumor Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Gene Therapies for Tumor Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Gene Therapies for Tumor Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Gene Therapies for Tumor Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Gene Therapies for Tumor Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Gene Therapies for Tumor Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Gene Therapies for Tumor Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Gene Therapies for Tumor Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Gene Therapies for Tumor Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Gene Therapies for Tumor Treatment Revenue Share by Type (2021-2032) Figure 44. China Gene Therapies for Tumor Treatment Revenue Share by Application (2021-2032) Figure 45. Asia Gene Therapies for Tumor Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Gene Therapies for Tumor Treatment Revenue Share by Type (2021-2032) Figure 47. Asia Gene Therapies for Tumor Treatment Revenue Share by Application (2021-2032) Figure 48. Asia Gene Therapies for Tumor Treatment Revenue Share by Region (2021-2032) Figure 49. Japan Gene Therapies for Tumor Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Gene Therapies for Tumor Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Gene Therapies for Tumor Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Gene Therapies for Tumor Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Gene Therapies for Tumor Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Gene Therapies for Tumor Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Gene Therapies for Tumor Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Gene Therapies for Tumor Treatment Revenue Share by Type (2021-2032) Figure 57. SAMEA Gene Therapies for Tumor Treatment Revenue Share by Application (2021-2032) Figure 58. SAMEA Gene Therapies for Tumor Treatment Revenue Share by Country (2021-2032) Figure 59. Brazil Gene Therapies for Tumor Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Gene Therapies for Tumor Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Gene Therapies for Tumor Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Gene Therapies for Tumor Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Gene Therapies for Tumor Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Gene Therapies for Tumor Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Gene Therapies for Tumor Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Gene Therapies for Tumor Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Gene Therapies for Tumor Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Gene Therapies for Tumor Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Gene Therapies for Tumor Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Oncolytic Virotherapy
  • Gene Transfer
  • Gene Induced Immunotherapy
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Shanghai Sunway
  • Novartis
  • Amgen
  • Sibiono
  • Gilead Sciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Gene Therapies for Tumor Treatment Market by Type
  3. 1.2.1 Global Gene Therapies for Tumor Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Oncolytic Virotherapy
  5. 1.2.3 Gene Transfer
  6. 1.2.4 Gene Induced Immunotherapy
  7. 1.3 Gene Therapies for Tumor Treatment Market by Application
  8. 1.3.1 Global Gene Therapies for Tumor Treatment Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospital
  10. 1.3.3 Clinic
  11. 1.3.4 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Gene Therapies for Tumor Treatment Market Dynamics
  1. 2.1 Gene Therapies for Tumor Treatment Industry Trends
  2. 2.2 Gene Therapies for Tumor Treatment Industry Drivers
  3. 2.3 Gene Therapies for Tumor Treatment Industry Opportunities and Challenges
  4. 2.4 Gene Therapies for Tumor Treatment Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Gene Therapies for Tumor Treatment Market Perspective (2021-2032)
  2. 3.2 Global Gene Therapies for Tumor Treatment Growth Trends by Region
  3. 3.2.1 Global Gene Therapies for Tumor Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Gene Therapies for Tumor Treatment Market Size by Region (2021-2026)
  5. 3.2.3 Global Gene Therapies for Tumor Treatment Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Gene Therapies for Tumor Treatment Revenue by Players
  2. 4.1.1 Global Gene Therapies for Tumor Treatment Revenue by Players (2021-2026)
  3. 4.1.2 Global Gene Therapies for Tumor Treatment Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Gene Therapies for Tumor Treatment Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Gene Therapies for Tumor Treatment Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Gene Therapies for Tumor Treatment Key Players Headquarters & Area Served
  7. 4.4 Global Gene Therapies for Tumor Treatment Players, Product Type & Application
  8. 4.5 Global Gene Therapies for Tumor Treatment Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Gene Therapies for Tumor Treatment Market CR5 and HHI
  11. 4.6.3 2025 Gene Therapies for Tumor Treatment Tier 1, Tier 2, and Tier 3
5 Gene Therapies for Tumor Treatment Market Size by Type
  1. 5.1 Global Gene Therapies for Tumor Treatment Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Gene Therapies for Tumor Treatment Revenue by Type (2021-2032)
  3. 5.3 Global Gene Therapies for Tumor Treatment Revenue Market Share by Type (2021-2032)
6 Gene Therapies for Tumor Treatment Market Size by Application
  1. 6.1 Global Gene Therapies for Tumor Treatment Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Gene Therapies for Tumor Treatment Revenue by Application (2021-2032)
  3. 6.3 Global Gene Therapies for Tumor Treatment Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Shanghai Sunway
  2. 7.1.1 Shanghai Sunway Company Information
  3. 7.1.2 Shanghai Sunway Business Overview
  4. 7.1.3 Shanghai Sunway Gene Therapies for Tumor Treatment Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Shanghai Sunway Gene Therapies for Tumor Treatment Product Portfolio
  6. 7.1.5 Shanghai Sunway Recent Developments
  7. 7.2 Novartis
  8. 7.2.1 Novartis Company Information
  9. 7.2.2 Novartis Business Overview
  10. 7.2.3 Novartis Gene Therapies for Tumor Treatment Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Novartis Gene Therapies for Tumor Treatment Product Portfolio
  12. 7.2.5 Novartis Recent Developments
  13. 7.3 Amgen
  14. 7.3.1 Amgen Company Information
  15. 7.3.2 Amgen Business Overview
  16. 7.3.3 Amgen Gene Therapies for Tumor Treatment Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Amgen Gene Therapies for Tumor Treatment Product Portfolio
  18. 7.3.5 Amgen Recent Developments
  19. 7.4 Sibiono
  20. 7.4.1 Sibiono Company Information
  21. 7.4.2 Sibiono Business Overview
  22. 7.4.3 Sibiono Gene Therapies for Tumor Treatment Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Sibiono Gene Therapies for Tumor Treatment Product Portfolio
  24. 7.4.5 Sibiono Recent Developments
  25. 7.5 Gilead Sciences
  26. 7.5.1 Gilead Sciences Company Information
  27. 7.5.2 Gilead Sciences Business Overview
  28. 7.5.3 Gilead Sciences Gene Therapies for Tumor Treatment Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Gilead Sciences Gene Therapies for Tumor Treatment Product Portfolio
  30. 7.5.5 Gilead Sciences Recent Developments
8 North America
  1. 8.1 North America Gene Therapies for Tumor Treatment Revenue (2021-2032)
  2. 8.2 North America Gene Therapies for Tumor Treatment Revenue by Type (2021-2032)
  3. 8.2.1 North America Gene Therapies for Tumor Treatment Revenue by Type (2021-2026)
  4. 8.2.2 North America Gene Therapies for Tumor Treatment Revenue by Type (2027-2032)
  5. 8.3 North America Gene Therapies for Tumor Treatment Revenue Share by Type (2021-2032)
  6. 8.4 North America Gene Therapies for Tumor Treatment Revenue by Application (2021-2032)
  7. 8.4.1 North America Gene Therapies for Tumor Treatment Revenue by Application (2021-2026)
  8. 8.4.2 North America Gene Therapies for Tumor Treatment Revenue by Application (2027-2032)
  9. 8.5 North America Gene Therapies for Tumor Treatment Revenue Share by Application (2021-2032)
  10. 8.6 North America Gene Therapies for Tumor Treatment Revenue by Country
  11. 8.6.1 North America Gene Therapies for Tumor Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Gene Therapies for Tumor Treatment Revenue by Country (2021-2026)
  13. 8.6.3 North America Gene Therapies for Tumor Treatment Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Gene Therapies for Tumor Treatment Revenue (2021-2032)
  2. 9.2 Europe Gene Therapies for Tumor Treatment Revenue by Type (2021-2032)
  3. 9.2.1 Europe Gene Therapies for Tumor Treatment Revenue by Type (2021-2026)
  4. 9.2.2 Europe Gene Therapies for Tumor Treatment Revenue by Type (2027-2032)
  5. 9.3 Europe Gene Therapies for Tumor Treatment Revenue Share by Type (2021-2032)
  6. 9.4 Europe Gene Therapies for Tumor Treatment Revenue by Application (2021-2032)
  7. 9.4.1 Europe Gene Therapies for Tumor Treatment Revenue by Application (2021-2026)
  8. 9.4.2 Europe Gene Therapies for Tumor Treatment Revenue by Application (2027-2032)
  9. 9.5 Europe Gene Therapies for Tumor Treatment Revenue Share by Application (2021-2032)
  10. 9.6 Europe Gene Therapies for Tumor Treatment Revenue by Country
  11. 9.6.1 Europe Gene Therapies for Tumor Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Gene Therapies for Tumor Treatment Revenue by Country (2021-2026)
  13. 9.6.3 Europe Gene Therapies for Tumor Treatment Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Gene Therapies for Tumor Treatment Revenue (2021-2032)
  2. 10.2 China Gene Therapies for Tumor Treatment Revenue by Type (2021-2032)
  3. 10.2.1 China Gene Therapies for Tumor Treatment Revenue by Type (2021-2026)
  4. 10.2.2 China Gene Therapies for Tumor Treatment Revenue by Type (2027-2032)
  5. 10.3 China Gene Therapies for Tumor Treatment Revenue Share by Type (2021-2032)
  6. 10.4 China Gene Therapies for Tumor Treatment Revenue by Application (2021-2032)
  7. 10.4.1 China Gene Therapies for Tumor Treatment Revenue by Application (2021-2026)
  8. 10.4.2 China Gene Therapies for Tumor Treatment Revenue by Application (2027-2032)
  9. 10.5 China Gene Therapies for Tumor Treatment Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Gene Therapies for Tumor Treatment Revenue (2021-2032)
  2. 11.2 Asia Gene Therapies for Tumor Treatment Revenue by Type (2021-2032)
  3. 11.2.1 Asia Gene Therapies for Tumor Treatment Revenue by Type (2021-2026)
  4. 11.2.2 Asia Gene Therapies for Tumor Treatment Revenue by Type (2027-2032)
  5. 11.3 Asia Gene Therapies for Tumor Treatment Revenue Share by Type (2021-2032)
  6. 11.4 Asia Gene Therapies for Tumor Treatment Revenue by Application (2021-2032)
  7. 11.4.1 Asia Gene Therapies for Tumor Treatment Revenue by Application (2021-2026)
  8. 11.4.2 Asia Gene Therapies for Tumor Treatment Revenue by Application (2027-2032)
  9. 11.5 Asia Gene Therapies for Tumor Treatment Revenue Share by Application (2021-2032)
  10. 11.6 Asia Gene Therapies for Tumor Treatment Revenue by Country
  11. 11.6.1 Asia Gene Therapies for Tumor Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Gene Therapies for Tumor Treatment Revenue by Country (2021-2026)
  13. 11.6.3 Asia Gene Therapies for Tumor Treatment Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Gene Therapies for Tumor Treatment Revenue (2021-2032)
  2. 12.2 SAMEA Gene Therapies for Tumor Treatment Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Gene Therapies for Tumor Treatment Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Gene Therapies for Tumor Treatment Revenue by Type (2027-2032)
  5. 12.3 SAMEA Gene Therapies for Tumor Treatment Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Gene Therapies for Tumor Treatment Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Gene Therapies for Tumor Treatment Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Gene Therapies for Tumor Treatment Revenue by Application (2027-2032)
  9. 12.5 SAMEA Gene Therapies for Tumor Treatment Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Gene Therapies for Tumor Treatment Revenue by Country
  11. 12.6.1 SAMEA Gene Therapies for Tumor Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Gene Therapies for Tumor Treatment Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Gene Therapies for Tumor Treatment Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst